• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种高通量方法研究乳腺癌细胞中 E2:ERα 信号转导的生理学。

A high throughput method to study the physiology of E2:ERα signaling in breast cancer cells.

机构信息

Department of Sciences, Section Biomedical Sciences and Technology, University Roma Tre, Rome, Italy.

出版信息

J Cell Physiol. 2018 May;233(5):3713-3722. doi: 10.1002/jcp.26251. Epub 2017 Nov 24.

DOI:10.1002/jcp.26251
PMID:29091270
Abstract

17β-estradiol (E2) regulates diverse physiological effects including cell proliferation through the estrogen receptor α (ERα), which as a transcription factor drives gene transcription and as an extra-nuclear localized receptor triggers the membrane-dependent activation of diverse kinase cascades. E2 also modifies ERα intracellular levels via diverse intracellular mechanisms. In this way, the E2-acivated ERα integrates signaling cascades with the modulation of receptor intracellular concentration and with the induction of DNA synthesis and ultimately drives cell proliferation. In turn, E2 signaling deregulation can cause many diseases including breast cancer (BC). Recently, we performed a Western blotting (WB)-based screen to identify novel pathways affecting ERα intracellular levels and BC cell proliferation. However, because WB lacks high throughput potential, a high-content method to detect all aspects of E2:ERα signaling (nuclear and extra-nuclear receptor activity, ERα levels, E2-induced DNA synthesis) is desirable. Here, we set up a rapid way to measure E2:ERα signaling in 96-well plate format. To demonstrate its robustness, we also challenged 4OH-tamoxifen resistant (Tam-Res) BC cells with a library of anti-cancer drugs and identified methotrexate (MTX) as a molecule inducing ERα degradation and preventing BC cell proliferation. Overall, our research provides a high-content technique to study the physiology of E2:ERα signaling in cells and further suggests a possible anti-ERα and anti-proliferative use for MTX in Tam-Res BCs.

摘要

17β-雌二醇(E2)通过雌激素受体α(ERα)调节多种生理效应,包括细胞增殖,作为转录因子,它驱动基因转录,作为核外定位的受体,触发多种激酶级联的膜依赖性激活。E2 还通过多种细胞内机制来改变 ERα 的细胞内水平。通过这种方式,E2 激活的 ERα 将信号级联与受体细胞内浓度的调节以及 DNA 合成的诱导结合起来,最终驱动细胞增殖。反过来,E2 信号失调会导致许多疾病,包括乳腺癌(BC)。最近,我们进行了基于 Western blot(WB)的筛选,以鉴定影响 ERα 细胞内水平和 BC 细胞增殖的新途径。然而,由于 WB 缺乏高通量的潜力,因此需要一种高内涵的方法来检测 E2:ERα 信号的各个方面(核和核外受体活性、ERα 水平、E2 诱导的 DNA 合成)。在这里,我们建立了一种在 96 孔板格式中测量 E2:ERα 信号的快速方法。为了证明其稳健性,我们还用一组抗癌药物对 4-羟基他莫昔芬耐药(Tam-Res)BC 细胞进行了挑战,并确定甲氨蝶呤(MTX)是一种诱导 ERα 降解并阻止 BC 细胞增殖的分子。总的来说,我们的研究提供了一种高内涵技术,用于研究细胞中 E2:ERα 信号的生理学,并进一步表明 MTX 在 Tam-Res BC 中可能具有抗 ERα 和抗增殖作用。

相似文献

1
A high throughput method to study the physiology of E2:ERα signaling in breast cancer cells.一种高通量方法研究乳腺癌细胞中 E2:ERα 信号转导的生理学。
J Cell Physiol. 2018 May;233(5):3713-3722. doi: 10.1002/jcp.26251. Epub 2017 Nov 24.
2
Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.出乎意料的是,丙型肝炎病毒抑制剂会对乳腺癌中的 17β-雌二醇信号产生影响。
Int J Mol Sci. 2020 May 12;21(10):3418. doi: 10.3390/ijms21103418.
3
A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.一项功能性药物再利用筛选发现卡非佐米可作为一种药物,可防止 17β-雌二醇:ERα 信号和乳腺癌细胞增殖。
Mol Cell Endocrinol. 2018 Jan 15;460:229-237. doi: 10.1016/j.mce.2017.07.027. Epub 2017 Jul 29.
4
Modulation of 17β-Estradiol Signaling on Cellular Proliferation by Caveolin-2.小窝蛋白-2对17β-雌二醇信号传导在细胞增殖方面的调节作用
J Cell Physiol. 2016 Jun;231(6):1219-25. doi: 10.1002/jcp.25218. Epub 2015 Oct 23.
5
Activation of ClC-3 chloride channel by 17β-estradiol relies on the estrogen receptor α expression in breast cancer.17β-雌二醇对ClC-3氯通道的激活依赖于乳腺癌中雌激素受体α的表达。
J Cell Physiol. 2018 Feb;233(2):1071-1081. doi: 10.1002/jcp.25963. Epub 2017 Jun 9.
6
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.计算机筛选 ERα 下调调节剂发现噻吨嗪类药物可作为原发性、4-羟基他莫昔芬耐药和 Y537S ERα 表达的乳腺癌细胞的增殖抑制剂。
Cell Oncol (Dordr). 2018 Dec;41(6):677-686. doi: 10.1007/s13402-018-0400-x. Epub 2018 Sep 4.
7
Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.未折叠蛋白反应的预期性雌激素激活与雌激素受体α阳性乳腺癌的细胞增殖及不良预后相关。
Oncogene. 2015 Jul;34(29):3760-9. doi: 10.1038/onc.2014.292. Epub 2014 Sep 29.
8
A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.一种新型抗雌激素发现平台将美国食品药品监督管理局(FDA)批准的咪唑类抗真菌药物鉴定为针对表达雌激素受体α(ERα)的乳腺癌细胞的生物活性化合物。
Int J Mol Sci. 2021 Mar 13;22(6):2915. doi: 10.3390/ijms22062915.
9
Lysosomal function is involved in 17β-estradiol-induced estrogen receptor α degradation and cell proliferation.溶酶体功能参与了 17β-雌二醇诱导的雌激素受体 α 降解和细胞增殖。
PLoS One. 2014 Apr 15;9(4):e94880. doi: 10.1371/journal.pone.0094880. eCollection 2014.
10
Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.蛋白激酶D1调节雌激素受体α阳性乳腺癌细胞对17β-雌二醇的生长反应,并导致患者预后不良。
J Cell Mol Med. 2014 Dec;18(12):2536-52. doi: 10.1111/jcmm.12322. Epub 2014 Oct 7.

引用本文的文献

1
Rapid differentiation of estrogen receptor status in patient biopsy breast cancer aspirates with an optical nanosensor.利用光学纳米传感器快速鉴别患者活检乳腺癌抽吸物中的雌激素受体状态。
bioRxiv. 2024 Apr 1:2024.03.29.587397. doi: 10.1101/2024.03.29.587397.
2
Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.选择性抑制 ALK 和 MELK 对不同乳腺癌分子表型细胞系中 ERα 稳定性和细胞增殖的影响。
Sci Rep. 2024 Apr 8;14(1):8200. doi: 10.1038/s41598-024-59001-x.
3
A functional genetic screen for metabolic proteins unveils GART and the purine biosynthetic pathway as novel targets for the treatment of luminal A ERα expressing primary and metastatic invasive ductal carcinoma.
一项代谢蛋白的功能遗传筛选揭示了 GART 和嘌呤生物合成途径是治疗腔 A ERα 表达的原发性和转移性浸润性导管癌的新靶点。
Front Endocrinol (Lausanne). 2023 Apr 18;14:1129162. doi: 10.3389/fendo.2023.1129162. eCollection 2023.
4
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.评估乳腺癌细胞系对心脏糖苷的敏感性揭示了 ATP1B3 可能成为 ERα 表达乳腺癌个体化治疗的生物标志物。
Int J Mol Sci. 2022 Sep 21;23(19):11102. doi: 10.3390/ijms231911102.
5
The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor α (ERα)-positive breast cancer cells.抗病毒药物特拉匹韦通过降低雌激素受体 α(ERα)阳性乳腺癌细胞中的 FOXA1 表达诱导细胞死亡。
Mol Oncol. 2022 Oct;16(19):3568-3584. doi: 10.1002/1878-0261.13303. Epub 2022 Sep 3.
6
Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.临床上相关的 CHK1 抑制剂可消除野生型和 Y537S 突变型 ERα 在腔面原发性和转移性乳腺癌细胞中的表达和增殖。
J Exp Clin Cancer Res. 2022 Apr 13;41(1):141. doi: 10.1186/s13046-022-02360-y.
7
The Peculiar Estrogenicity of Diethyl Phthalate: Modulation of Estrogen Receptor α Activities in the Proliferation of Breast Cancer Cells.邻苯二甲酸二乙酯独特的雌激素活性:对雌激素受体α在乳腺癌细胞增殖中活性的调节
Toxics. 2021 Sep 25;9(10):237. doi: 10.3390/toxics9100237.
8
A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.一种新型抗雌激素发现平台将美国食品药品监督管理局(FDA)批准的咪唑类抗真菌药物鉴定为针对表达雌激素受体α(ERα)的乳腺癌细胞的生物活性化合物。
Int J Mol Sci. 2021 Mar 13;22(6):2915. doi: 10.3390/ijms22062915.
9
Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERα in Cells Modeling Primary and Metastatic Breast Cancer.哇巴因和地高辛在原发性和转移性乳腺癌细胞模型中激活蛋白酶体并导致雌激素受体α降解。
Cancers (Basel). 2020 Dec 19;12(12):3840. doi: 10.3390/cancers12123840.
10
The Network of Angiotensin Receptors in Breast Cancer.乳腺癌中的血管紧张素受体网络。
Cells. 2020 May 27;9(6):1336. doi: 10.3390/cells9061336.